US2009197836A1PendingUtilityA1
Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
Est. expiryJun 29, 2020(expired)· nominal 20-yr term from priority
A61K 31/175A61K 31/426A61K 45/06
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.
Claims
exact text as granted — not AI-modified1 - 114 . (canceled)
115 . A method of treating diabetes comprising administering to a mammal having diabetes a pharmaceutical composition comprising a pharmaceutically effective amount of at least one insulin secretagogue and a pharmaceutically effective amount of at least one FBPase inhibitor, wherein said insulin secretagogue is selected from a group consisting of sulfonylurea antidiabetic agents and non-sulfonylurea antidiabetic agents, and the FBPase inhibitor is selected from the group consisting of formulae I and IA and pharmaceutically acceptable prodrugs and salts thereof, wherein formulae I and IA are as follows:
wherein in vivo or in vitro compounds of formulae I and IA are converted to M-PO 3 2− , which inhibits FBPase, and wherein:
Y is independently selected from —O— and —NR 6 , with the provisos that:
when Y is —O—, the R 1 attached to —O— is independently selected from —H, alkyl, optionally substituted aryl, optionally substituted alicyclic where the cyclic moiety contains a carbonate or a thiocarbonate, optionally substituted -arylalkyl, —C(R 2 ) 2 OC(O)NR 2 2 , —NR 2 —C(O)—R 3 , —C(R 2 ) 2 —OC(O)R 3 , —C(R 2 ) 2 —O—C(O)OR 3 , —C(R 2 ) 2 OC(O)SR 3 , -alkyl-S—C(O)R 3 , -alkyl-S—S-alkylhydroxy, and -alkyl-S—S—S-alkylhydroxy;
when Y is —NR 6 —, the R 1 attached to —NR 6 — is independently selected from —H, —[C(R 2 ) 2 ] q —COOR 3 , —C(R 4 ) 2 COOR 3 , —[C(R 2 ) 2 ] q —C(O)SR, and -cycloalkylene-COOR 3 , where q is 1 or 2;
when only one Y is —O—, which —O— is not part of a cyclic group containing the other Y, the other Y is —N(R 18 )—(CR 12 R 13 )—C(O)—R 14 ; and
when Y is independently selected from —O— and —NR 6 , together R 1 and R 1 are alkyl-S—S-alkyl- and form a cyclic group, or together, R 1 and R 1 form:
wherein
a) V is selected from the group of aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkynyl and 1-alkenyl; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, said cyclic group is fused to an aryl group at the beta and gamma position to the Y adjacent to V; or
Z is selected from the group of —CHR 2 OH , —CHR 2 OC(O)R 3 —CHR 2 OC(S)R 3 , —CHR 2 OC(S)OR 3 , —CHR 2 OC(O)SR 3 , —CHR 2 OCO 2 R 3 , —OR 2 , —SR 2 , —CHR 2 N 3 , —CH 2 aryl, —CH(aryl)OH, —CH(CH═CR 2 2 )OH, —CH(C≡CR 2 )OH, —R 2 , —NR 2 2 , —OCOR 3 , —OCO 2 R 3 , —SCOR 3 , —SCO 2 R 3 , —NHCOR 2 , —NHCO 2 R 3 , —CH 2 NHaryl, —(CH 2 ) p —OR 2 , and —(CH 2 ) p —SR 2 , where p is an integer 2 or 3; or
together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
W and W′ are independently selected from the group of —H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl and 1-alkynyl; or
together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
b) V 2 , W 2 and W″ are independently selected from the group of —H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl;
Z 2 is selected from the group of —CHR 2 OC(O)R 3 , —CHR 2 OC(S)R 3 , —CHR 2 OCO 2 R 3 , —CHR 2 OC(O)SR, —CHR 2 OC(S)OR 3 , —CH(aryl)OH, —CH(CH═CR 2 2 )OH, —CH(C≡CR 2 )OH, —SR 2 , —CH 2 NHaryl, —CH 2 aryl; or
together V 2 and Z 2 are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 ring atoms, optionally containing 1 heteroatom, and substituted with hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from a Y attached to phosphorus;
c) Z′ is selected from the group of —OH, —OC(O)R 3 , —OCO 2 R 3 , and —OC(O)SR 3 ;
D′ is —H;
D″ is selected from the group of —H, alkyl, —OR 1 , —OH, and —OC(O)R 3 ;
each W 3 is independently selected from the group of —H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl;
with the proviso that:
i) V, Z, W, W′ are not all —H and V 2 , Z 2 , W 2 , W″ are not al —H; and
R 2 is selected from R 3 and —H;
R 3 is selected from alkyl, aryl, alicyclic, and aralkyl;
each R 4 is independently selected from the group of —H, alkylene, -alkylenearyl and aryl, or together R 4 and R 4 are connected via 2-6 atoms, optionally including one heteroatom selected from the group of O, N, and S;
R 6 is selected from —H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;
n is an integer from 1 to 3;
R 18 is independently selected from H, lower alkyl, aryl, and aralkyl, or, together, R 12 and R 18 are connected via 1-4 carbon atoms to form a cyclic group;
each R 12 and each R 13 is independently selected from 11, lower alkyl, lower aryl, lower aralkyl, all optionally substituted, or R 12 and R 13 , together, are connected via 2-6 carbon atoms, optionally including 1 heteroatom selected from the group of O, N, and S, to form a cyclic group;
each R 14 is independently selected from —OR 17 , —N(R 17 ) 2 , —NHR 17 , —SR 17 , and —NR 2 R 20 ;
R 15 is selected from —H, lower alkyl, lower aryl, and lower aralkyl, or, together, R 15 and R 16 are connected via 2-6 atoms to form a cyclic group, wherein the cyclic group optionally includes one heteroatom selected from O, N, and S;
R 16 is selected from —(CR 12 R 13 ) n —C(O)—R 14 , —H, lower alkyl, lower aryl, and lower aralkyl, or, together, R 15 and R 16 are connected via 2-6 atoms to form a cyclic group, wherein the cyclic group optionally includes one heteroatom selected from O, N, and S;
each R 17 is independently selected from lower alkyl, lower aryl, and lower aralkyl, or, when R 14 is —N(R 17 ) 2 , together, both R 17 s are connected via 2-6 atoms to form a cyclic group, wherein the cyclic group optionally includes one heteroatom selected from O, N, and S;
R 20 is selected from the group of —H, lower R 3 , and —C(O)-lower R 3 ; and
M is selected from the group consisting of
wherein:
U 6 and V 6 are independently selected from hydrogen, hydroxy, and acyloxy, or, when taken together, U 6 and V 6 form a lower cyclic ring containing at least one oxygen;
W 6 is selected from amino and lower alkyl amino; and
Z 6 is selected from alkyl and halogen;
wherein:
A2 is selected from —NR 8 2 , —NHSO 2 R 3 , —OR 25 , —SR 25 , halogen, lower alkyl, —CON(R 4 ) 2 , guanidine, amidine, —H, and perhaloalkyl;
E 2 is selected from —H. halogen, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, —CN, and —NR 7 2 ;
X 3 is selected from -alkyl(hydroxy); -alkyl-; -alkynyl-; -aryl-; -carbonyl-alkyl-; -1,1-dihaloalkyl-; -alkoxyalkyl-; -alkyloxy-; -alkylthioalkyl-; -alkylthio-; -alkylaminocarbonyl-; -alkylcarbonylamino-; -alicyclic-; -aralkyl-; -alkylaryl-; -alkoxycarbonyl-; -carbonyloxyalkyl-; -alkoxycarbonylamino-; and -alkylaminocarbonylamino-, all optionally substituted, with the proviso that X 3 is not substituted with —COOR 2 , —SO 3 H, or —PO 3 R 2 2 ;
Y 3 is selected from —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, —C(O)R 3 , —S(O) 2 R 3 , —C(O)—R 11 , —CONHR 3 , —NR 2 2 , and —OR 3 , all, except H, optionally substituted;
each R 4 is independently selected from —H and alkyl, or, together, both R 4 s form a cyclic alkyl group;
R 25 is selected from lower alkyl, lower aryl, lower aralkyl, and lower alicyclic;
each R 7 is independently selected from —H, lower alkyl, lower alicyclic, lower aralkyl, lower aryl, and —C(O)R 10 ;
each R 8 is independently selected from —H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, —C(O)R 10 , or, together, both R 8 s form a bidentate alkyl;
R 10 is selected from —H, lower alkyl, —NH 2 , lower aryl, and lower perhaloalkyl; and
R 11 is selected from alkyl, aryl, —NR 2 2 , and —OR 2 ;
wherein:
A, E, and L are independently selected from —NR 8 2 , —NO 2 , —H, —OR 7 , —SR 7 , —C(O)NR 2 , halo, —COR 11 , —SO 2 R 3 , guanidine, amidine, —NHSO 2 R 25 , —SO 2 NR 4 2 , —CN, sulfoxide, perhaloacyl, perhaloalkyl, perhaloalkoxy, C 1 -C 8 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, and lower alicyclic, or, together, A and L form a cyclic group, or, together, L and E form a cyclic group, or, together, E and J form a cyclic group selected from the group of aryl, cyclic alkyl, and heterocyclic;
J is selected from —NR 8 2 , —NO 2 , —H, —OR 7 , —SR 7 , —C(O)NR 4 2 , halo,
—C(O)R 11 , —CN, sulfonyl, sulfoxide, perhaloalkyl, hydroxyalkyl, perhaloalkoxy, alkyl, haloalkyl, aminoalkyl, alkenyl, alkynyl, alicyclic, aryl, and aralkyl, or, together, J and Y form a cyclic group selected from the group of aryl, cyclic alkyl, and heterocyclic alkyl;
X 3 is selected from -alkyl(hydroxy); -alkyl-; -alkynyl-; -aryl-; -carbonyl-alkyl-; 1,1-dihaloalkyl-; -alkoxyalkyl-; -alkyloxy-; -alkylthioalkyl-; -alkylthio-; -alkylaminocarbonyl-; -alkylcarbonylamino-; -alicyclic-; -aralkyl-; -alkylaryl-; -alkoxycarbonyl-; -carbonyloxyalkyl-; -alkoxycarbonylamino-; and -alkylaminocarbonylamino-, all optionally substituted, with the proviso that X 3 is not substituted with —COOR 2 , —SO 3 H, or —PO 3 R 2 ;
Y 3 is selected from —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, —C(O)R 3 , —S(O) 2 R 3 , —C(O)—R 11 , —CONHR 3 , —NR 2 2 , and —OR 3 , all except H are optionally substituted;
each R 4 is independently selected from —H and alkyl, or, together, both R 4 s form a cyclic alkyl group;
R 25 is selected from lower alkyl, lower aryl, lower aralkyl, and lower alicyclic;
each R 7 is independently selected from —H, lower alkyl, lower alicyclic, lower aralkyl, lower aryl, and —C(O)R 10 ;
each R 8 is independently selected from —H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, —C(O)R 10 , or, together, both R 8 s form a bidentate alkyl;
R 10 is selected from —H, lower alkyl, —NH 2 , lower aryl, and lower perhaloalkyl; and
R 11 is selected from alkyl, aryl, —NR 2 2 , and —OR 2 ;
wherein:
B 5 is selected from —NH—, —N═ and —CH—;
D 5 is selected from
Q 5 is selected from —C═ and —N—;
with the provisos that:
when B 5 is —NH—, Q 5 is —C═ and D 5 is
when B 5 is —CH═, Q 5 is —N— and D 5 is
and
when B 5 is —N═, D 5 is
and Q 5 is —C═;
A, E, and L are independently selected from —NR 8 2 , —NO 2 , —H, —OR 7 , —SR 7 , —C(O)NR 4 2 , halo, —COR 1 , —SO 2 R 3 , guanidine, amidine, —NHSO 2 R 25 , —SO 2 NR 4 2 , —CN, sulfoxide, perhaloacyl, perhaloalkyl, perhaloalkoxy, C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, and lower alicyclic, or, together, A and L form a cyclic group, or, together, L and E form a cyclic group, or, together, E and J form a cyclic group selected from the group of aryl, cyclic alkyl, and heterocyclic;
J is selected from —NR 8 2 , —NO 2 , —H, —OR 7 , —SR 7 , —C(O)NR 4 2 , halo, —C(O)R 11 , —CN, sulfonyl, sulfoxide, perhaloalkyl, hydroxyalkyl, perhaloalkoxy, alkyl, haloalkyl, aminoalkyl, alkenyl, alkynyl, alicyclic, aryl, and aralkyl, or together with Y forms a cyclic group selected from the group of aryl, cyclic alkyl and heterocyclic alkyl;
X 3 is selected from -alkyl(hydroxy), -alkyl-, -alkynyl-, -aryl-, -carbonyl-alkyl-, -1,1-dihaloalkyl-, -alkoxyalkyl-, -alkyloxy-, -alkylthioalkyl-, -alkylthio-, -alkylaminocarbonyl-, -alkylcarbonylamino-, -alicyclic-, -aralkyl-, -alkylaryl-, -alkoxycarbonyl-, -carbonyloxyalkyl-,-alkoxycarbonylamino-, and -alkylaminocarbonylamino-, all optionally substituted; with the proviso that X 3 is not substituted with —COOR 2 , —SO 3 H, or —PO 3 R 2 2 ;
Y 3 is selected from —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, —C(O)R 3 , —S(O) 2 R 3 , —C(O)—R 11 , —CONHR 3 , —NR 2 2 , and —OR 3 , all except H are optionally substituted;
R 4 is independently selected from —H and alkyl, or together R 4 and R 4 form a cyclic alkyl group;
R 25 is selected from lower alkyl, lower aryl, lower aralkyl, and lower alicyclic;
R 7 is independently selected from —H, lower alkyl, lower alicyclic, lower aralkyl, lower aryl, and —C(O)R 10 ;
R 8 is independently selected from —H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, —C(O)R 10 , or together they form a bidentate alkyl;
R 10 is selected from —H, lower alkyl, —NH 2 , lower aryl, and lower perhaloalkyl;
R 11 is selected from alkyl, aryl, —NR 2 2 and —OR 3 ;
wherein:
each G is independently selected from C, N, O, S, and Se, and wherein not more than one G is O, S, or Se, and not more than one G is N;
each G′ is independently selected from C and N and wherein no more than two G′ groups are N;
A is selected from —H, —NR 4 2 , —CONR 4 2 , —CO 2 R 3 , halo, —S(O)R 3 , —SO 2 R 3 , alkyl, alkenyl, alkynyl, perhaloalkyl, haloalkyl, aryl, —CH 2 OH, —CH 2 NR 4 2 , —CH 2 CN, —CN, —C(S)NH 2 , —OR 3 , —SR 3 , —N 3 , —NHC(S)NR 4 2 , —NHAc, and null;
each B and D are independently selected from —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, aralkyl, alkoxyalkyl, —C(O)R 11 , —C(O)SR 3 , —SO 2 R 11 , —S(O)R 3 , —CN, —NR 9 2 , —OR 3 , —SR 3 , perhaloalkyl, halo, —NO 2 , and null, all except —H, —CN, perhaloalkyl, —NO 2 , and halo are optionally substituted;
E is selected from —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, alkoxyalkyl, —C(O)OR 3 , —CONR 4 2 , —CN, —NR 9 2 , —NO 2 , —OR 3 , —SR 3 , perhaloalkyl, halo, and null, all except —H, —CN, perhaloalkyl, and halo are optionally substituted;
J is selected from —H and null;
X is an optionally substituted linking group that links R 5 to the phosphorus atom via 2-4 atoms, including 0-1 heteroatoms selected from N, O, and S, except that if X is urea or carbamate there are 2 heteroatoms, measured by the shortest path between R 5 and the phosphorus atom, and wherein the atom attached to the phosphorus is a carbon atom, and wherein X is selected from furan-2,5-diyl, -alkyl(hydroxy), -alkynyl-, -heteroaryl-, -carbonylalkyl-, -1,1-dihaloalkyl-, -alkoxyalkyl-, -alkyloxy-, -alkylthioalkyl-, -alkyl-, -thio-, -alkylaminocarbonyl-, -alkylcarbonylamino-, -alkoxycarbonyl-, -carbonyloxyalkyl-, -alkoxycarbonylamino-, and -alkylaminocarbonylamino-, all optionally substituted; with the proviso that X is not substituted with —COOR 2 , —SO 3 H, or —PO 3 R 2 2 ;
R 2 is selected from R 3 and —H;
R 3 is selected from alkyl, aryl, alicyclic, and aralkyl;
each R 4 is independently selected from —H, and alkyl, or together R 4 and R 4 form a cyclic alkyl group;
each R 9 is independently selected from —H, alkyl, aralkyl, and alicyclic, or together R 9 and R 9 form a cyclic alkyl group or a heterocyclic group where the heteroatom is selected from the group of O, S and N;
R 11 is selected from alkyl, aryl, —NR 2 2 , and —OR 2 ;
and with the proviso that:
1) when G′ is N, then the respective A, B, D, or E is null;
2) at least one of A and B, or A, B, D, and E is not selected from —H or null;
3) when R 5 is a six-membered ring, then X is not any 2 atom linker, an optionally substituted -alkyloxy-, or an optionally substituted -alkylthio-;
4) when G is N, then the respective A or B is not halogen or a group directly bonded to G via a heteroatom;
5) when X is not an -aryl-group, then R 5 is not substituted with two or more aryl groups;
wherein:
G″ is selected from —O— and —S—;
A 2 , L 2 , E 2 , and J 2 are selected from —NR 4 2 , —NO 2 , —H, —OR 2 , —SR 2 , —C(O)NR 4 2 , halo, —COR 11 , —SO 2 R 3 , guanidinyl, amidinyl, aryl, aralkyl, alkoxyalkyl, —SCN, —NHSO 2 R 9 , —SO 2 NR 4 2 , —CN, —S(O)R 3 , perhaloacyl, perhaloalkyl, perhaloalkoxy, C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, and lower alicyclic, or together L 2 and E 2 or E 2 and J 2 form an annulated cyclic group;
X 2 is selected from —CR 2 2 —, —CF 2 —, —CR 2 2 —O—, —CR 2 2 —S—, —C(O)—O—, —C(O)—S—, —C(S)—O—, and —CR 2 2 —NR 19 —, and wherein in the atom attached to the phosphorus is a carbon atom; with the proviso that X 2 is not substituted with —COOR 2 , —SO 3 H, or —PO 3 R 2 2 ;
R 2 is selected from R 3 and —H;
R 3 is selected from alkyl, aryl, alicyclic, and aralkyl;
each R 4 is independently selected from —H, and alkyl, or together R 4 and R 4 form a cyclic alkyl group;
each R 9 is independently selected from —H, alkyl, aralkyl, and alicyclic, or together R 9 and R 9 form a cyclic alkyl group;
R 11 is selected from alkyl, aryl, —NR 2 2 , and —OR 2 ;
R 19 is selected from lower alkyl, —H, and —COR 2 .
116 . The method according to claim 115 , wherein M is
A″ is of —H, —NR 4 2 , —CONR 4 2 , —CO 2 R 3 , halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 perhaloalkyl, C 1 -C 6 haloalkyl, aryl, —CH 2 OH, —CH 2 NR 4 2 , —CH 2 CN, —CN, —C(S)NH 2 , —OR 3 , —SR 3 , —N 3 , —NHC(S)NR 4 2 , and —NHAc;
B″ is —H, alkyl, alkenyl, alkynyl, aryl, alicyclic, aralkyl, alkoxyalkyl, —C(O)R 11 , —C(O)SR 3 , —SO 2 R 11 , —S(O)R 3 , —CN, —NR 9 2 , —OR 3 , —SR 3 , perhaloalkyl, and halo, all except —H, —CN, perhaloalkyl, and halo are optionally substituted;
X is selected from the group consisting of methylenoxycarbonyl and furan-2,5-diyl;
YR 1 is OH or Y is NR 6 , wherein R 6 is selected from H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, or lower acyl; and R 1 is independently selected from the group consisting of —H, —[C(R 2 ) 2 ] q —COOR 3 , —C(R 4 ) 2 COOR 3 , —[C(R 2 ) 2 ] q —C(O)SR 3 , and -cycloalkylene-COOR 3 , wherein R 4 is, independently, alkyl or H and R 3 is alkyl, aryl, alicyclic or aralkyl.
117 . The method according to claim 116 , wherein A″ is —NH 2 , —Cl, —Br, or —CH 3 ; B″ is —H, —C(O)OR 3 , —C(O)SR 3 , C 1 -C 6 alkyl, C(O)R 11 , alicyclic, halo, heteroaryl, or —SR 3 and all except —H, and halo are optionally substituted.
118 . The method according to claim 117 , wherein A″ is —NH 2 ; B″ is a C 1 -C 6 alkyl or C(O)R 11 , wherein R 11 is alkyl.
119 . The method according to claim 116 , wherein X is furan-2,5-diyl.
120 . The method according to claim 116 , wherein when Y is NR 6 , R 6 is selected from H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, or lower acyl; and R 1 is independently selected from the group consisting of —H, —[C(R 2 ) 2 ] q —COOR 3 , —C(R 4 ) 2 COOR 3 , —[C(R 2 ) 2 ] q —C(O)SR 3 , and -cycloalkylene-COOR 3 , wherein R 4 is, independently, alkyl or H and R 3 is alkyl, aryl, alicyclic or aralkyl.
121 . The method according to claim 120 , wherein Y is NR 6 and R 6 is H; and R 1 is —C(R 4 ) 2 COOR 3 , wherein R 4 is, independently, H or methyl; and R 3 is alkyl.
122 . The method according to claim 116 , wherein A″ is —NH 2 ; B″ is a C 1 -C 6 alkyl or C(O)R 11 , wherein R 11 is alkyl; and X is selected from the group consisting of methylenoxycarbonyl and furan-2,5-diyl.
123 . The method according to claim 122 , wherein X is furan-2,5-diyl.
124 . The method according to claim 116 , wherein A″ is —NH 2 ; B″ is a C1-C6 alkyl or C(O)R 11 , wherein R 11 is alkyl; and YR1 is OH.
125 . The method according to claim 116 , wherein A″ is —NH 2 ; B″ is a C1-C6 alkyl or C(O)R 11 , wherein R 11 is alkyl; Y is NR 6 and R 6 is H; and R 1 is —C(R 4 ) 2 COOR 3 , wherein R 4 is, independently, H or methyl; and R 3 is alkyl.
126 . The method according to claim 116 , wherein X is furan-2,5-diyl and YR 1 is OH.
127 . The method according to claim 116 , wherein X is furan-2,5-diyl; Y is NR 6 and R 6 is H; and R 1 is —C(R 4 ) 2 COOR 3 , wherein R 4 is, independently, H or methyl; and R 3 is alkyl.
128 . The method according to claim 116 , wherein A″ is —NH 2 ; B″ is a C 1 -C 6 alkyl or C(O)R 11 , wherein R 11 is alkyl; X is selected from the group consisting of methylenoxycarbonyl and furan-2,5-diyl; and YR 1 is OH.
129 . The method according to claim 128 , wherein X is furan-2,5-diyl.
130 . The method according to claim 116 , wherein A″ is —NH 2 ; B″ is a C1-C6 alkyl or C(O)R 11 , wherein R 11 is alkyl; X is selected from the group consisting of methylenoxycarbonyl and furan-2,5-diyl; Y is NR 6 and R 6 is H; and R 1 is —C(R 4 ) 2 COOR 3 , wherein R 4 is, independently, H or methyl; and R 3 is alkyl.
131 . The method according to claim 130 , wherein X is furan-2,5-diyl.
132 . The method according to claim 116 , wherein said FBPase inhibitor is
Compound J
133 . The method according to claim 115 , wherein said sulfonylurea antidiabetic agent is glyburide and said FBPase inhibitor is
Compound J
134 . The method according to claim 115 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
135 . The method according to claim 134 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibomuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
136 . The method according to claim 132 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
137 . The method according to claim 136 , wherein said sulfonylurea antidiabetic agent is selected from glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
138 . The method according to claim 130 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
139 . The method according to claim 138 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
140 . The method according to claim 131 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
141 . The method according to claim 140 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
142 . The method according to claim 128 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
143 . The method according to claim 142 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
144 . The method according to claim 129 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
145 . The method according to claim 144 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.
146 . The method according to claim 117 , wherein said sulfonylurea antidiabetic agent is a compound of formula XV:
wherein
A is selected from hydrogen, halo, alkyl, alkanoyl, aryl, aralkyl, heteroaryl, and cycloalkyl; and
B is selected from alkyl, cycloalkyl, and heterocyclic alkyl.
147 . The method according to claim 146 , wherein said sulfonylurea antidiabetic agent is selected from glyburide, glisoxepid, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, and glimepiride.Join the waitlist — get patent alerts
Track US2009197836A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.